Myecfo LLC Buys New Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Myecfo LLC acquired 17,497 Arrowhead Pharmaceuticals shares worth approximately $1.43 million in the second quarter, making ARWR its 15th-largest holding at 0.5% of its portfolio.
• Institutional ownership remains substantial at 62.61%, with BlackRock initiating a position valued at roughly $1.21 billion and several other firms increasing their holdings.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year but missed earnings estimates with a loss of $1.36 per share. Analysts maintain a “Moderate Buy” consensus with an average price target of $97.33.

Myecfo LLC bought a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,497 shares of the biotechnology company's stock, valued at approximately $1,426,000. Arrowhead Pharmaceuticals comprises approximately 0.5% of Myecfo LLC's holdings, making the stock its 15th largest position.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $1,208,838,000. Geode Capital Management LLC raised its holdings in Arrowhead Pharmaceuticals by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company's stock worth $216,799,000 after purchasing an additional 133,921 shares during the period. Baker BROS. Advisors LP raised its holdings in Arrowhead Pharmaceuticals by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock worth $144,441,000 after purchasing an additional 504,883 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company's stock valued at $138,619,000 after purchasing an additional 6,264 shares in the last quarter. Finally, Fred Alger Management LLC lifted its position in Arrowhead Pharmaceuticals by 497.4% during the fourth quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock valued at $121,693,000 after purchasing an additional 1,526,164 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $89.41 on Thursday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The business's 50-day simple moving average is $82.33 and its two-hundred day simple moving average is $72.64. The stock has a market cap of $12.59 billion, a PE ratio of -39.74 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $19.56 and a 52 week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same period last year, the company earned ($1.26) EPS. The business's revenue was up 171.0% on a year-over-year basis. As a group, analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Royal Bank Of Canada lifted their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an "outperform" rating in a research report on Friday, May 8th. JPMorgan Chase & Co. boosted their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Sanford C. Bernstein increased their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research note on Monday. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $97.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source